prednisone / Generic mfg. - LARVOL DELTA

A RARE CASE OF PULMONARY ARTERY STENOSIS FROM ANCA-ASSOCIATED VASCULITIS: THE DIAGNOSTIC ROLE OF CARDIAC MRI (ACC 2026) - "LGE and increased T2 signal of the arterial wall confirmed active inflammatory vasculitis.Decision-Making: The patient was treated with prednisone, rituximab, and azathioprine with symptomatic improvement. ANCA-associated pulmonary artery vasculitis is rare and may present with nonspecific symptoms, delaying diagnosis and treatment. Early recognition is essential before development of right heart failure. CMR is a critical diagnostic tool, in assessing right heart function and vascular anatomy."

Clinical • ANCA Vasculitis • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Vasculitis

Prednisone (AAD 2026) - No abstract available

Double Trouble… or Double Triumph? Dual Biologic Therapy in Refractory Hidradenitis Suppurativa (AAD 2026) - "Adalimumab, secukinumab, and bimekizumab are currently FDA-approved for moderate-to-severe HS, with adalimumab demonstrating response rates of 42–59%...He had minimal response to doxycycline, benzoyl peroxide wash, and clindamycin, and subsequently failed adalimumab, secukinumab, acitretin, dapsone, cefadroxil, prednisone, laser hair removal, and topical agents over two years. Given inadequate disease control, infliximab was added to ongoing secukinumab... Dual biologic therapy may represent a promising option for patients with severe, refractory HS unresponsive to monotherapy with currently available systemic treatments, including FDA-approved biologics used individually. Larger studies are needed to clarify long-term efficacy and safety."

Acne Vulgaris • Aesthetic Medicine • Conjunctivitis • Dermatology • Dry Eye Disease • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Acne Treated with Tumor Necrosis Factor Inhibitors: A Retrospective Case Series (AAD 2026) - "33/34 received adalimumab and 4/34 received infliximab, with 3 patients treated with both sequentially...Concurrent therapies included isotretinoin (26%), antibiotics (32%), spironolactone (3%), prednisone (15%)... Acne patients treated with TNFi were primarily young, male, and racially/ethnically diverse. Addition of TNFi therapy was effective in most patients, supporting its role in severe or refractory acne, including adolescent populations. This series is the largest to date and contributes to limited evidence for biologics in severe acne."

Retrospective data • Acne Vulgaris • Hidradenitis Suppurativa • Immunology • Oncology

Severe New-Onset Pemphigus Vulgaris Following COVID-19 Infection: A Case Report and Scoping Review (AAD 2026) - "She was discharged with a prednisone taper, antimicrobial prophylaxis, and rituximab infusion plan, with subsequent improvement. This case highlights severe, treatment-refractory PV triggered by COVID-19 infection, adding to evidence of SARS-CoV-2–related immune dysregulation. Clinicians should maintain vigilance for persistent mucosal and cutaneous erosions post-COVID to ensure early biopsy, diagnosis, and aggressive therapy, reducing morbidity."

Case report • Clinical • Review • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Pemphigus Vulgaris • Respiratory Diseases

Treatment of Granulation Tissue in the Setting of Acne Fulminans with Timolol (AAD 2026) - "Our patient continued isotretinoin with two courses of oral prednisone, oral cephalexin, and intralesional corticosteroids. This case highlights successful control of AF while continuing isotretinoin therapy and introduces topical timolol as a potentially useful adjunct for associated vascular lesions that may be treatment resistant. Further studies are needed to clarify the role of topical beta-blockers in severe inflammatory acne and its complications."

Acne Vulgaris • Hematological Disorders • Hidradenitis Suppurativa • Immunology • Inflammation

Clinical Response of a Patient with Steroid-Refractory Lichen Planus to Nemolizumab Therapy: A Case Report (AAD 2026) - "The patient’s rash and severe pruritus were refractory to oral antihistamines, several topical corticosteroids, and oral prednisone. Further studies are needed to characterize the mechanism of pruritus in LP and the role of IL-31 in pathogenesis. Prospective trials evaluating nemolizumab’s safety and efficacy in LP are also warranted."

Case report • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Lichen Planus • Prurigo Nodularis • Pruritus

Systemic Burdens and Care Gaps in Eczema and Psoriasis: Insights from the NIH All of Us Research Program (AAD 2026) - "These findings suggest a critical role for earlier screening, proactive cardiovascular risk assessment, and interdisciplinary management in eczema and psoriasis. The high prednisone use may highlight a care gap and the need to educate both providers and patients about its potential to exacerbate disease. Dermatologic care models should evolve beyond cutaneous symptoms to integrate mental health support, chronic disease prevention, and comprehensive medication safety education, ensuring more effective, patient-centered management."

Asthma • Atopic Dermatitis • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Cognitive Disorders • Depression • Dermatology • Developmental Disorders • Genetic Disorders • Immunology • Inflammation • Myocardial Infarction • Obesity • Psoriasis • Pulmonary Disease • Respiratory Diseases

Immune Checkpoint Inhibitor-Eczema: Results from a Multi-Institutional Cohort Study (AAD 2026) - "Over one third received systemic steroids, while eleven patients received dupilumab; all nine evaluable dupilumab-treated patients achieved complete resolution (CTCAE grade 0) without adverse effects...In a time-varying Cox regression adjusting for age, ECOG, and rash grade, high-dose steroid exposure (>60 mg prednisone) was independently associated with worse PFS (HR 5.31, 95% CI 1.87–15.01, p = .0017). These findings suggest that both early and high-dose systemic steroid use may be associated with worse oncologic outcomes in patients with eczematous cirAEs, consistent with corticosteroid-related attenuation of ICI benefit. This highlights the need for wider access to targeted therapies for cancer patients using dermatology-led, steroid-sparing strategies."

Checkpoint inhibition • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Oncology

Eosinophilic-Rich Linear Immunoglobulin A Bullous Dermatosis (AAD 2026) - "The drug-induced variant is most commonly linked to vancomycin, though other implicated agents include trimethoprim-sulfamethoxazole, amoxicillin, nonsteroidal anti-inflammatory drugs, simvastatin, cyclosporine, furosemide, lithium, and various additional medications...Treatments—including metronidazole gel, prednisone, triamcinolone, mupirocin, and doxycycline—provided minimal relief...Eosinophil-rich LABD has been infrequently reported in both adult and pediatric patients. Known associations include COVID-19 vaccination, parvovirus B19 infection, hematologic malignancies, and certain medications."

Alopecia • Cough • Dermatology • Hematological Malignancies • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Novel Coronavirus Disease • Orthopedics • Pruritus • Respiratory Diseases

Characterization and management of serpentine supravenous reaction: a seven-patient case series of taxane-associated reactions (AAD 2026) - "Introduction: Serpentine supravenous reaction (SSR) is a rare cutaneous complication involving the superficial venous network after intravenous administration of chemotherapeutic agents, most commonly taxanes.1 The variety and spectra of clinical courses, severities, histopathologies, and treatments have been underdocumented for SSR.2,3 We present a seven-patient case series of SSR associated with docetaxel and paclitaxel...Treatments included topical corticosteroids (n=6) and systemic prednisone (n=1)... SSR presents with consistent onset and distribution but has a broader clinical spectrum than has been reported, ranging from asymptomatic pigmentation to severe inflammatory reactions with vesiculobullous morphology. Improved understanding of this reaction coupled with prompt dermatologic consultation may allow for earlier treatment intervention, minimizing severity of the reaction and long-term sequelae."

Clinical • Dermatitis • Immunology • Pruritus

Severe Presentations of Cutaneous Lupus in Patients on Immune Checkpoint Inhibitors (ICIs) (AAD 2026) - "A 77-year-old female with endometrial adenocarcinoma developed widespread tense bullae and mucosal erosions after three cycles of pembrolizumab with carboplatin/paclitaxel...Treatment included discontinuation of pembrolizumab, high-dose prednisone, and hydroxychloroquine, which successfully achieved disease control. The second case, a 74-year-old female with stage IIIC clear cell uterine carcinoma, developed a diffuse morbilliform eruption with flaccid bullae and denuded plaques after four cycles of dostarlimab with carboplatin/paclitaxel...Despite systemic steroid therapy and comprehensive supportive wound care, her course was complicated by malnutrition and multisystem organ involvement, and she expired approximately three months after onset of the rash. These cases emphasize the importance of early biopsy, clinicopathologic correlation, and prompt immunosuppressive therapy in managing rare, severe cutaneous irAEs during ICI treatment (2)."

Checkpoint inhibition • Clinical • Cutaneous Lupus Erythematosus • Dermatitis • Discoid Lupus Erythematosus • Endometrial Adenocarcinoma • Endometrial Cancer • Immunology • Inflammatory Arthritis • Lupus • Oncology • Solid Tumor • Steven-Johnson Syndrome • Uterine Cancer

Dupilumab for Eosinophilic Fasciitis: A Retrospective Study (AAD 2026) - "Dupilumab enabled steroid-sparing in 8 patients: 4 discontinued steroids after a mean of 5 (2-11) months, while the remainder decreased average daily prednisone from 39 mg to 6 mg. No adverse events led to treatment discontinuation. These findings suggest that dupilumab is a potential steroid-sparing alternative for patients with relapsing or refractory EF."

Retrospective data • Eosinophilia • Fibrosis • Inflammation • IL13 • IL4

Prospective Evaluation of Patient-Reported Disease Flare in Hidradenitis Suppurativa (AAD 2026) - "Doing nothing was the most common response to flare symptoms (38%), followed by using topical (36.3%) and oral medications (26.3%), such as oral antibiotics (16%), painkillers (5.3%), and prednisone (2.3%)... We report the results of the first 25 enrolled patients; 18 have completed the study (97% response rate) and 5 were terminated. The average age was 33.6 years (SD=9.73). Most patients were female (88%) and white (48%) and had Hurley Stage II disease (52%)."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Pruritus

Ulcerative Necrobiosis Lipoidica in the Setting of Oropharyngeal Epstein-Barr Virus Positive Diffuse LargCell Lymphoma and Glucose-6-Phosphate Dehydrogenase Deficiency: A Case Report (AAD 2026) - "Anti-inflammatory topical clobetasol 0.05% ointment was initiated as well as a saline based solution containing hypochlorous acid for wound cleansing. Due to secondary infection, the patient’s topical regimen was modified to include gentamicin 0.1% ointment and mupirocin 2% ointment followed by eventual broad-spectrum IV antibiotics. Notably, dapsone was avoided due to known G6PD as well as other immunosuppressants in the setting of DLBCL and ongoing chemotherapy with rituximab, cyclophosphamide, doxorubicin, (vincristine), and prednisone (R-CHOP) which had induced neutropenia and thrombocytopenia...Additionally, pegfilgrastim and platelet infusions for neutropenia and thrombocytopenia were administered after initiating R-CHOP. The noninfectious granulomatous reactions may have been an early sign of the underlying lymphoma, suggesting DLBCL as a contributing factor to NL disease pathogenesis."

Case report • Clinical • B Cell Lymphoma • Diabetes • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Metabolic Disorders • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Immunodeficiency • Thrombocytopenia

Nicolau Syndrome in a Child: A Rare Injection-Related Complication (AAD 2026) - "We present a pediatric case of NS following IM leuprolide...He was treated with antihistamines, NSAIDs, and a prednisone injection...Although etiology remains unclear, NS is considered an unpredictable complication independent of number of injections or medication type, dose, or injection frequency, and recurrence is not expected. This case adds to limited pediatric literature, highlights diagnostic challenges, and supports continued IM injection use when clinically indicated."

Clinical • Bone Marrow Transplantation • Cardiovascular • Hematological Disorders • Thrombosis

Asymptomatic hyperpigmented reticulated patches and subtle indurated plaques on the extremities as presentation of polyarteritis nodosa in skin of color (AAD 2026) - "She was treated with prednisone and methotrexate with improvement over 6 months. As erythema is subtler in skin of color patients, atypical presentations are important to document. In SOC patients with hyperpigmented reticulated patches on the extremities, we recommend a low threshold for deeper biopsies to query for PAN."

Vasculitis

Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis (AAD 2026) - "Over several years, he failed multiple therapies including topical corticosteroids, oral prednisone, and systemic immunosuppressants (methotrexate, cyclosporine, mycophenolate). Biologic agents such as dupilumab, ixekizumab, and apremilast were also ineffective...Initial risankizumab monotherapy (IL-23 inhibitor) reduced BSA from 65% to 20%. Due to incomplete clearance, deucravacitinib (TYK2 inhibitor) was added, resulting in further improvement to 4% BSA over 16 months. The combination was well tolerated with no adverse effects. This case highlights the potential efficacy of dual IL-23 and TYK2 inhibition and supports individualized, flexible treatment strategies for refractory psoriasis."

Monotherapy • Atopic Dermatitis • Dermatology • Immunology • Pruritus • Psoriasis • IL17A • IL23A • IL4 • TYK2

A Rare Case of Radiation-Induced Bullous Pemphigoid in Metastatic Merkel Cell Carcinoma Successfully Treated with Dupilumab. (AAD 2026) - "Despite receiving 4 cycles of Nivolumab, his MCC progressed and had to undergo surgical excision for bleeding chest wall mass...As oral prednisone failed to control his BP flare-ups and we were unable to taper steroids, Dupilumab was initiated...Patient was started on Pembrolizumab and chemotherapy for his MCC recurrence after he was informed about the risk of BP flare-up with immune checkpoint inhibitors...This case is a novel contribution in the usage of dupilumab in radiation-induced BP, as it has been reported only in a couple of instances. We want to highlight that Dupilumab could be an effective therapeutic option in the setting of refractory radiation-induced BP and in patients on immune checkpoint inhibitors."

Clinical • Metastases • Breast Cancer • Bullous Pemphigoid • Dermatology • Dermatopathology • Esophageal Cancer • Genetic Disorders • Hypertension • Immunology • Kaposi Sarcoma • Merkel Cell Carcinoma • Non-melanoma Skin Cancer • Obesity • Oncology • Sarcoma • Skin Cancer • Solid Tumor

Oral Dexamethasone for Outpatient Management of Cytokine Release Syndrome in Patients Receiving Bispecific T-cell Engager Therapy for Multiple Myeloma (HOPA 2026) - "Background/Rationale: Four bispecific T-cell engagers (BiTEs), elranatamab, linvoseltamab, talquetamab, and teclistamab, are currently indicated for relapsed/refractory multiple myeloma.1-5 All currently available BiTEs share a US Boxed Warning of cytokine release syndrome (CRS)...Patients will be excluded if they were pregnant, had active infections, prescribed corticosteroid dose equivalent or greater than prednisone 10 mg by mouth daily, received prophylactic tocilizumab, or received BiTEs as part of a clinical trial... Results are pending. Conclusions/ This study may validate safety of outpatient management of CRS with oral dexamethasone and/or oral acetaminophen to decrease hospital admissions."

Bispecific • Clinical • Cytokine release syndrome • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Evaluating Institutional Prophylactic Granulocyte Colony-Stimulating Factor Practices and Febrile Neutropenia Outcomes in Patients Receiving Triple Therapy for de novo Metastatic Hormone-Sensitive Prostate Cancer (HOPA 2026) - "The PEACE-1 and ARASENS trials, demonstrated significantly improved progression-free and overall survival with the addition of ARPI (abiraterone/prednisone and darolutamide, respectively) to ADT in combination with docetaxel, leading to FDA approval and guideline inclusion of "triple therapy" for mHSPC1,2. Pending"

Metastases • Febrile Neutropenia • Genito-urinary Cancer • Hepatology • Hormone Sensitive Prostate Cancer • Liver Failure • Neutropenia • Oncology • Prostate Cancer • Solid Tumor

Evaluation of outpatient administration of dose adjusted EPOCH-R using a single-bag 96-hour infusion of etoposide phosphate, vincristine, and doxorubicin (HOPA 2026) - "Background/Rationale: A component of DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) includes a 96-hour continuous infusion of etoposide, doxorubicin, and vincristine.1 To facilitate outpatient administration of DA-EPOCH-R, previous experiences reported single- or two-day bags of etoposide, doxorubicin, and vincristine due to the concentration dependent solubility and stability of etoposide, which requires additional infusion center visits for bag changes.2-10 Etoposide phosphate is a water-soluble prodrug of etoposide with improved stability. Results pending."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Infusion-Related Reactions in Patients Treated With Axatilimab for Chronic Graft-Versus-Host Disease in the AGAVE-201 Study (HOPA 2026) - P2 | "At the time of the IRR, 13 patients (56.5%) were receiving concomitant medications, mainly prednisone (26.1%), prednisolone (21.7%), topical hydrocortisone (13.0%), famotidine (13.0%), hydrocortisone (8.7%), and diphenhydramine (8.7%). Of the 239 patients who received axatilimab during AGAVE-201, 23 patients (9.6%) experienced 38 IRRs. IRR incidence by group was 11/79 patients (13.9%) for 0.3 mg/kg Q2W, 5/81 patients (6.2%) for 1 mg/kg Q2W, and 7/79 patients (8.9%) for 3 mg/kg Q4W. Among these 23 patients, cGVHD most commonly involved the eyes (69.6%), skin (69.6%), and lungs (56.5%)."

Clinical • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Urticaria

Optimizing Early Recognition and Pharmacologic Management Pathways for Pediatric T-Lymphoblastic Lymphoma Presenting With Mediastinal Compression in a Hematology/Oncology Service. (HOPA 2026) - "Pharmacy processes assessed included availability of induction agents (dexamethasone, CAL-asparaginase, bortezomib), timing of pericardiocentesis and thoracentesis support medications, and chemotherapy verification workflows...Application of these findings led COG to the construction of a unified pharmacist-supported pathway in the upcoming AALL2331 study for newly diagnosed T-LL prioritizing: (1) Prednisone-based induction, (2) Bortezomib during induction and delayed intensification, (3) elimination of prophylactic cranial radiation, (4) enhanced toxic-effect monitoring for pancreatitis, thrombosis, and early remission death risks, and (5) exploring the role of Daratumomab at first presentation of T-LL...Integration of updated COG data supports structured decision-making and reduction of treatment delays. Standardizing pharmacy workflows may decrease morbidity associated with airway compromise and improve adherence to contemporary evidence-based regimens."

Clinical • Cardiovascular • Hematological Disorders • Hematological Malignancies • Lymphoblastic Lymphoma • Lymphoma • Pancreatitis • Pediatrics • T Acute Lymphoblastic Leukemia • Thrombosis

Real-World Comparison of Adverse Effects Between Nivolumab plus Ipilimumab Versus Nivolumab plus Relatlimab in First-Line Treatment of Unresectable Metastatic Melanoma: A Veterans Health Administration Observational Cohort Study (HOPA 2026) - "Patients with active brain metastases, autoimmune diseases, or those receiving >10 mg/day of prednisone or equivalent within 2 weeks before initiating treatment will be excluded. Pending"

Adverse events • Clinical • Metastases • Observational data • Real-world • Real-world evidence • Immunology • Melanoma • Solid Tumor